# Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis

> **NCT04638426** · PHASE2 · UNKNOWN · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 196 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** HL237 tablet
- **DRUG:** Placebo of HL237 tablet

## Key facts

- **NCT ID:** NCT04638426
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-10
- **Primary completion:** 2021-05
- **Final completion:** 2021-08
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2020-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638426, "Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04638426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*